Resveratrol may support cardiovascular health

October 3, 2012

A study presented at the 24th Scientific Meeting of the International Society of Hypertension shows that resveratrol may improve circulatory function in obese, mildly hypertensive adults.

The double blind placebo-controlled trial was conducted by a research team led by Professor Peter Howe at the University of South Australia, Adelaide. Twenty-eight subjects were supplemented with 75 mg of DSM’s Resvida resveratrol per day for six weeks. This resulted in a 23% increase in vasodilator function (measured by flow-mediated dilatation, FMD), compared with the placebo. The extent of improvement was greater in subjects with poorer initial vasodilator function. This is important as a decreased vasodilator response is an early biomarker for cardiovascular risk and associated with obesity and hypertension.

The results substantiate previous findings by the same research group that single doses of Resvida can improve vasodilator function. This new study shows that this acute effect persists with regular Resvida supplementation, resulted in continued improvement of circulatory function.

Although many food and beverages contain resveratrol, it is only in small amounts. The highest concentrations are found in whole grapes used for making red wine. Based on existing studies, the best results can be achieved with doses starting at 30 mg per day in order to see the health benefits. This would equal the amount of resveratrol contained in about 10 bottles of red wine. Resvida is suitable for use in various types of foods and dietary supplements and it has little or no impact on flavor and color characteristics.

Press release